A large proportion of lower-risk myelodysplastic syndromes (MDS) respond to erythropoiesis-stimulating agents (ESA), but most responses are transient. We updated a previously reported cohort of lower-risk MDS patients treated with ESA and analyzed outcomes after ESA failure. In 120 patients with primary resistance and 66 patients with relapse after an initial response to ESA, the 5-year cumulative incidence of acute myeloid leukemia (AML) after failure was 18.9% and 11.6%, respectively (P ¼ 0.20). Median overall survival (OS) after failure was 40.1 and 44.9 months (P ¼ 0.35), respectively. We further categorized patients as 'early failures' (including resistance and relapse after o6 months of response), or 'later failures' (that is, relapse after X6 months). The 5-year cumulative incidence of AML and median OS after failure in early and later failure were 21.6% and 9% (P ¼ 0.02) and 36.7 and 54.3 months (P ¼ 0.02), respectively. Early failure to ESA and a baseline diagnosis of refractory anemia with excess blasts (RAEB)-1 were independent prognostic factors for AML progression and, along with trisomy 8, for shorter OS. Median OS from treatment onset was 40, 90.7 and 65.8 months in early failure, later failure and no relapse, respectively (P ¼ 0.001). Lower-risk MDS with early failure to ESA have a relatively unfavorable outcome, and should be offered alternative treatments.
INTRODUCTION
Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis leading to blood cytopenias, and by a variable risk of transformation to acute myeloid leukemia (AML). 1 Probabilities of survival and AML transformation in MDS patients can be largely estimated by the International Prognostic Scoring System (IPSS) based on the number of cytopenias, results of cytogenetic analysis and percentage of bone marrow blasts, which categorizes patients into four groups with significantly different risk of progression to AML and survival. 2 IPSS low and intermediate-1 (int-1) risk subgroups have relatively favorable prognosis, and are often grouped as 'lower-risk' MDS.
The main clinical problem, in lower-risk MDS patients, is generally anemia. If one excepts lower-risk MDS with 5q deletion, which respond preferentially to lenalidomide, anemia responds in 30-50% of the other cases to erythropoiesis-stimulating agents (ESA), including recombinant erythropoietin (EPO) and darbepoetin (DAR). [3] [4] [5] [6] [7] Prognostic factors of erythroid response to ESA have been well identified, with better response rates in patients with no or limited red blood cell (RBC) transfusion requirement, low baseline serum EPO level and IPSS low or int-1. 3, 4 Response to ESA treatment may also be associated with a survival benefit compared with transfusional treatment alone, as suggested by two retrospective and one prospective study. [4] [5] [6] However, not all lower-risk MDS respond to ESA and, in responders, median response duration is in the range of 2 years, a majority of patients eventually relapsing with transfusiondependent anemia. 4 The outcome of those patients, in terms of AML progression and survival, is unknown. Several drugs, including the hypomethylating agents azacitidine and decitabine, and lenalidomide (even in patients without 5q deletion), have shown efficacy in correcting anemia in a proportion of those patients, but their impact on progression to AML and survival is unknown.
As a basis for second-line treatments in anemia of lower-risk MDS failing treatment with ESA, we analyzed the outcome of patients who did not respond to or relapsed after response to ESA in a previously published cohort of 403 patients.
PATIENTS AND METHODS

Patients and outcome definitions
We recently reported results of ESA (r-Hu-EPO or DAR±granulocyte colony-stimulating factor (G-CSF)) in 403 MDS patients with anemia (treated in centers of the Groupe Francophone des Myé lodysplasies (GFM), either in GFM trials or according to GFM recommendations, that is, hemoglobin o10 g/dl, with or without RBC transfusion requirement; Park et al. 4 and Supplementary Figure 1) . Of those patients, 142 were excluded from the present analysis because IPSS was int-2/high or could not be determined, or because they had chronic myelomonocytic leukemia, other types of MDS/myeloproliferative neoplasms, therapy-related MDS, unclassified MDS or because cytogenetics included del 5q (that have less favorable response to ESA) 7 or chromosome 3q26 abnormalities (that carry, although they are classified in the 'intermediate' IPSS group, poor prognosis) 8 (Supplementary Figure 1) . Eight additional patients with very rapid (p6 weeks) progression to higher-risk MDS (N ¼ 1) or to AML (N ¼ 7) at the time of ESA failure were excluded, leaving a final cohort of 253 patients, of whom 67 were still responders to ESA at last follow-up or death.
Patients had started ESA treatment between 1998 and 2006, and data were reanalyzed 5 years after the last patient inclusion (at the reference date of 1 June 2011). Patients had received at least 12 weeks of rHu-EPO (epoietin a or b, 60 000 IU per week, or DAR 300 mg per week), as described previously. 4 Some patients with failure of ESA alone after 12 weeks received, in particular if required or suggested by the clinical trial to which they participated, G-CSF combined to ESA for an additional 12 weeks. Responses at 12 weeks of ESA treatment (or 24 weeks of ESA þ G-CSF), initially recorded according to the International Working Group (IWG) 2000 criteria, 9 had been systematically re-evaluated according to the World Health Organization (WHO) 2006 criteria and defined by an increase in hemoglobin level by X1.5 g/dl and/or decrease of transfusion needs by at least 4 RBC units during the previous 8 weeks. 10 Relapse was defined as a decrease in hemoglobin concentration by X1.5 g/dl or transfusion dependence in the absence of another explanation such as bleeding, infection, B9 or B12 deficiency, or ESA discontinuation or dose reduction. 10 Transformation to AML was defined as an increase in bone marrow blasts to X20%.
11 Causes of death were coded as MDS-related (including AML transformation, infection, hemorrhage), cardiac (excluding cerebrovascular causes of death), neoplastic other than acute leukemia, others and unknown.
Statistical methods
Survival was estimated using the Kaplan-Meier method. 12 Progression to AML and overall survival (OS) after failure were calculated from the time of relapse in patients who lost response to ESA and from failure assessment made 12 weeks after the onset of ESA for patients with primary resistance, or 24 weeks for those patients who still failed to respond after an additional 12 weeks of G-CSF combined with ESA. The reason why different time points were used in the two failure groups was that those time points were the most clinically relevant in each group, corresponding to the time when AML risk and OS had to be evaluated for further therapeutic decisions. However, we also compared in the different patient subgroups OS from the onset of ESA and, in that case, the two failure subgroups were also compared with patients who did not relapse after response to ESA. Patients who received bone marrow transplantation were censored at the time of transplantation.
OS curves were compared using the log-rank test. 13 Cumulative incidences of AML transformation were estimated taking into account the competing risk of death and compared using the Gray test. 14 Multivariate analysis on potential predictive variables for OS and cumulative incidence of AML was conducted with the Cox model and Fine and Gray test, respectively. 15 Categorical variables were created from continuous variables and survival and cumulative incidence of AML estimated across the strata.
Continuous variables were categorized according to the median value of patients with primary resistance except for thresholds known to be of clinical importance (such as 5% for marrow blasts). For multivariable analysis, only variables associated with outcome at the 5% level in univariable analyses were introduced in the model; moreover, all missing values were imputed as the median value computed on the sample; a stepwise selection procedure was performed to finally select those variables.
Cause-specific mortality was studied considering different causes of death as competing risks for calculation of OS. All calculations were performed with R version 2.8.1.
Cutoff points relative to response duration, which would be discriminant for OS and cumulative incidence of AML, were determined by randomly dividing the patient cohort in two subsamples of equal size, based on uniformly generated variables, using the median to define the two subsamples. The similarity of the two subsamples on OS was tested by the log-rank test across the subsamples. The first subsample was used for cutoff points screening and the second subsample for validation of the selected value.
RESULTS
Patient characteristics
In all, 253 patients with lower-risk non-del 5q MDS were analyzed, including 120 resistant to ESA (with or without G-CSF), 66 with erythroid relapse not explained by a concomitant increase in bone marrow blasts and 67 who responded and had not relapsed at last follow-up or death. Baseline characteristics of the three patient groups are shown in Table 1 . As expected, those three groups differed (significantly or as a trend) for parameters known to be associated with response and response duration to ESA, including WHO classification, multilineage dysplasia, IPSS, serum EPO level and RBC transfusion requirement. 3, 4 In the 186 patients with primary or secondary failure of ESA treatment, 43% received some treatment other than transfusions after ESA failure, including azacitidine (N ¼ 19), lenalidomide (N ¼ 11), thalidomide (N ¼ 29), all-trans retinoic acid (N ¼ 6), antithymocyte globulin (ATG)±cyclosporine (N ¼ 5) and other treatments (androgens, corticosteroids, vorinostat, bevacizumab, arsenic trioxide) (N ¼ 7). Another 12 patients received treatment only after progression to high-risk MDS or AML, including azacitidine (N ¼ 4), intensive chemotherapy (N ¼ 5) and allogeneic bone marrow transplantation (N ¼ 5). All other patients received only RBC transfusions. Iron chelation was used in 81% of the patients with RBC transfusion requirement.
Patients with primary resistance In the 120 patients with primary resistance to ESA, median followup was 84 months. Only three patients were lost to follow-up (all after o24 months).
The 3-, 5-and 7-year cumulative incidence of progression to AML after ESA failure was 15.4% (95% confidence interval (CI): 8.8-22), 18.9% (95% CI: 11.8-26.1) and 20.2% (95% CI: 12.7-27.8), respectively. Baseline IPSS was the only significant predictive factor of AML transformation (3-year cumulative incidence of AML 10.2% vs 23.9% in low vs int-1 IPSS, P ¼ 0.03).
Median OS after ESA failure was 40.1 months (95% CI: 31.5-51.4). Table 2 reports the univariate prognostic analyses of OS in those 120 patients with primary resistance. Of the six covariates associated with outcome at the 5% level (that is, age, gender, WHO classification, bone marrow blasts, IPSS and platelet count) and introduced jointly in the model, three were selected as adding to each other prognostic information, namely age (hazard ratio (HR) ¼ 1.06/10 years; 95% CI: 1.03-1.08; Po0.0001), gender (female vs male; HR ¼ 0.52; 95% CI: 0.33-0.83; P ¼ 0.006) and int-1 IPSS (HR ¼ 2.00; 95% CI: 1.21-3.33; P ¼ 0.007).
In all, 12 patients with primary resistance received azacitidine after ESA failure (three responded), one patient received ATG and four patients received intensive chemotherapy after progression to AML (three responded). Excluding patients who received azacitidine or ATG from the analysis of AML risk, and patients who received azacitidine, ATG or intensive chemotherapy for OS calculation, given the potential role of those treatments to alter the disease course, did not significantly alter outcome: 3-, 5-and 7-year cumulative incidence of AML and median OS after failure in the remaining patients were 13.9% (95% CI: 7.1-20.7), 18% (95% CI: 10.4-25.6), 19.5% (95% CI: 11.5-27.6) and 37.8 months (95% CI: 30-49.5), respectively.
Patients who relapsed
In the 66 patients who lost their response to ESA, median followup from relapse was 86 months. Six patients were lost to follow-up (two of them after o24 months). Median response duration had been 27.4 months (range 3-122 months).
After relapse, seven patients (10%) had AML transformation and overall cumulative incidence of AML after failure reached a plateau at 11.6% after 3 years (95% CI: 3.
4-19.8). Increased
Outcome of ESA refractory/relapsing MDS patients C Kelaidi et al cumulative incidence of AML was significantly correlated with the presence, at baseline, of at least two cytopenias, while diagnosis of RARS and lower serum EPO level were favorable predictive factors, but with borderline significance. In all, 34 patients had died and median OS after relapse was 44.9 months (95% CI: 30.7-not reached). OS was adversely affected by advanced age, shorter disease duration before onset of ESA, lower serum EPO level (p100 IU/l) and trisomy 8 ( Table 3) . As no risk category, except for age, included sufficient patient numbers for multivariable analysis, no such analysis was carried out.
After relapse, 11 patients received azacitidine (five responded), four received ATG (three responded) and one patient received intensive chemotherapy after subsequent AML transformation, followed by allogeneic bone marrow transplantation, at which time she was censored. Excluding those patients resulted in a cumulative incidence of AML of 12.3% after 3 years (95% CI: 2.9-26.7, with a plateau from 3-7 years) and a median OS of 37.8 months (95% CI: 27.9-not reached). Baseline trisomy 8 was the only factor significantly associated with shorter OS after this exclusion (median 7.5 vs 47.3 months in patients without trisomy 8: HR 11.9; P ¼ 0.004).
Early vs later failure We subsequently tried to assess whether response and response duration, in patients who failed ESA, were correlated to subsequent AML evolution and OS. We therefore compared responders vs non-responders, and non-responders plus patients relapsing within various intervals (6, 12 and 24 months) vs patients with later relapse.
AML progression and OS after ESA failure did not significantly differ between non-responders and patients who relapsed (P ¼ 0.20 and 0.35, respectively). When analyzing non-responders plus those who relapsed within 6, 12 and 24 months vs later relapses, all three cutoff values were equally accurate to discriminate patients for the AML risk.
To define the best cutoff for OS, we randomly generated two subsamples of equal sizes. As expected, OS was close across those random samples, with a log-rank test P-value of 0.85. The first subset was used to derive the cutoff point for early failure. Based on this sample, the selected cutoff point for prognostic value response duration was 6 months, with an estimated HR of death of 2.288 (95% CI: 1.325-3.952; P ¼ 0.003). The prognostic value of this classification was assessed and confirmed on the validation subsample, with an estimated HR of death of 2.2 (95% CI: 1.3-3.7; P ¼ 0.0038). Moreover, the cumulative incidence of AML was also increased in the early failure group, with a subdistribution hazard of AML estimated at 3.8 (95% CI: 1.11-13.0; P ¼ 0.029 by the Gray test).
Baseline characteristics of patients who did not respond to ESA or relapsed within 6 months ('early failure') and those who had later relapse ('late failure') are shown in Supplementary Table 1. Patients with early failure differed from those with later failure in Outcome of ESA refractory/relapsing MDS patients C Kelaidi et al that they had lower baseline hemoglobin levels, higher serum EPO levels and higher RBC transfusion requirements (Supplementary Table 1 ). The 3-, 5-and 7-year cumulative incidence of AML progression was 17.4% (95% CI: 9.8-24.9), 21.6% (95% CI: 13.3-29.9) and 23.1% (95% CI: 14.5-31.7) in patients with early failure vs a plateau of 9% between 3 and 7 years (95% CI: 2.6-15.5) in patients with later failure (P ¼ 0.02; Figure 1 ). OS after failure was shorter in the early failure subgroup (median 36.7 months (95% CI: 25.2-37.4)) compared with the later failure subgroup (median 54.3 months (95% CI 38.5-not reached), P ¼ 0.02; Table 4 and Figure 2) . Analyzing all failure patients by multivariate analysis, OS was predicted by age (HR ¼ 1.08/10 years; 95% CI: 1.05-1.11), refractory anemia with excess blasts (RAEB)-1 (HR ¼ 2.08; 95% CI: 1.32-3.26), response duration o6 months (HR ¼ 2.92; 95% CI: 1.92-4.43) and trisomy 8 (HR ¼ 2.42; 95% CI: 1.03-5.66). Based on the assumption that those risk factors were independent and hence that the hazard ratio of combined conditions is the product of individual hazard ratios, one may calculate expected median OS for patients with (a) early failure and trisomy 8: 7 months; (b) early failure and RAEB-1: 7 months; and (c) trisomy 8 and RAEB-1: 8 months. After adjustment for age, RAEB-1, early failure and trisomy 8 were significantly associated with shorter OS (HR 1.7, P ¼ 0.04; HR 1.5, P ¼ 0.03; HR 2.9, P ¼ 0.03, respectively).
Treatment received after failure was associated with a survival advantage (HR ¼ 0.46; 95% CI: 0.29-0.73; P ¼ 0.0011). After excluding patients who subsequently received hypomethylating agents, ATG or intensive chemotherapy, RAEB-1 (HR 1.8, P ¼ 0.02), early failure (HR 1.5, P ¼ 0.04) and trisomy 8 (HR 3, P ¼ 0.03) remained independent prognostic factors of shorter OS.
Comparison with patients with persisting response to ESA In all, 67 patients were still responders, with a median follow-up of 76.7 months from the onset of ESA. By definition, none had progressed to AML. Of these, 35 of them had died. Their median survival from the onset of ESA was 65.8 months (95% CI: 47.9-not reached) compared with 40.1 months (95% CI: 31-53.4) in patients with early ESA failure and 90.7 months (95% CI: 68.9-not reached) in patients with later failure (Figure 3) . The difference was significant with patients with early failure (P ¼ 0.01), but not with those with late failure (P ¼ 0.09).
Causes of death
The cause of death was documented in 77% of the cases (Table 5) . MDS-related causes (including AML transformation, infection and hemorrhage) and heart disease accounted for 44.5 and 19% of deaths in patients with early ESA failure compared with 39 and 12% in patients with later failure (P ¼ NS (nonsignificant)). However, 5-year cumulative incidence of MDS-related mortality from treatment onset was 32.5% in patients with early failure compared with 15.5% in those with later failure (P ¼ 0.02). The 5-year cumulative incidence of cardiac mortality from treatment onset was 12.8% in patients with early failure vs 5.1% in those with longer response (P ¼ 0.15). Outcome of ESA refractory/relapsing MDS patients C Kelaidi et al Predominant causes of death in patients without ESA failure were heart disease (17%), infections (14%), solid tumors (14%) and miscellaneous (stroke, fall, iatrogenic) (11%).
Results based on the ESA or ESA combination received In total, 21%, 43%, 28% and 8% of patients had received EPO (a or b) alone, EPO þ G-CSF, DAR alone and DAR þ G-CSF, respectively. None of the four treatment options affected OS after failure (HR ¼ 1.00; HR ¼ 0.87, 95% CI: 0.53-1.43, P ¼ 0.60; HR ¼ 0.99, 95% CI: 0.63-1.55, P ¼ 0.96; HR ¼ 1.56, 95% CI: 0.83-2.95, P ¼ 0.16, for EPO, EPO þ G-CSF, DAR, DAR þ G-CSF, respectively), but there was an effect, as a trend, on cumulative incidence of AML (at 5 years: 14.7%, 10.5%, 16.9%, 42.6%, respectively, P ¼ 0.058). However, only 15 patients had been treated by the combination of DAR and G-CSF and the trend towards a higher cumulative incidence of AML in that group may have been biased by the small number of patients. In addition, when other prognostic factors for AML (time to failure, RAEB-1) were taken into account, the type of ESA combination lost its prognostic value.
DISCUSSION
To our knowledge, this is the first report analyzing in detail the outcome of lower-risk MDS with primary or secondary failure to ESA. Our main finding in this cohort was that, in the absence of Outcome of ESA refractory/relapsing MDS patients C Kelaidi et al concomitant progression to higher-risk MDS or AML, patients who had primary refractoriness to ESA or relapsed within 6 months of response achievement ('early failures') had a relatively high risk of AML transformation (23.1%) and short survival (median 3 years), whereas patients who had responded to treatment and relapsed beyond 6 months ('late failure') had a more favorable outcome after failure with a 9% AML risk at 7 years and a median OS of 4.5 years. In multivariate analysis, early vs late failure was, along with RAEB-1 at onset of ESA, the only factor significantly associated with AML progression, while it was, along with RAEB-1 and trisomy 8, and after adjustment for age, associated with shorter survival. Categorization of patients with no response to ESA or relapse within 6 months on the one hand, and later relapse on the other hand, emerged as the most discriminant with regard to AML progression and OS compared with other categorizations, including no response vs relapse, or later cutoff values for relapse (12 and 24 months), and as shown by dividing the patient population in a learning and a validation cohort.
Of note is that, for clinical reasons, the study was landmarked in those two failure groups on date of ESA failure, which differed between them. Indeed, an important purpose of this study was to evaluate in individual patients the risk of AML progression and OS at the time an alternative treatment had to be considered (that is, after ESA failure). For the same reason, patients who concomitantly (or almost concomitantly) to ESA failure progressed to higher-risk MDS or AML were excluded from the analysis, as other types of treatments are generally considered in those patients.
In general, marrows were examined when disease progression was suspected based on substantial changes in peripheral blood or transfusion needs. Although not formally assessed, the potential variability in time of marrow assessment probably did not significantly affect measure of time to AML, as event-free survival after failure and OS after failure were very similar (38.6 vs 40.6 months, respectively). On the other hand, OS measured from the onset of ESA was also significantly shorter in patients with early failure than in patients with later failure, while this OS from the onset of ESA did not significantly differ between patients with late relapse and patients who did not relapse.
OS from treatment onset appeared slightly longer in patients with late failure compared to patients with no failure, but the difference was not significant (median 90.7 vs 65.8 months, P ¼ 0.09; Figure 3 ). Reasons for this slight difference possibly included group definition, the group with no failure consisting of patients with long response who were also long survivors, and also of patients with early death from causes other than AML who did not live long enough to have their response lost. Indeed, 8 of 35 deaths in the group of patients with no failure occurred within the first 2 years of treatment onset, that is, before the median response duration of patients with late failure (29.4 months).
In addition, because of the large number of tests of statistical significance performed, it should be recognized that type I errors may have occurred in the survival analysis.
Analysis of causes of death, in this elderly population of lowerrisk MDS frequently dying from causes other than MDS, was also made. With the restriction that the cause of death was known in only 77% of the patients, the cumulative incidence of death due or presumed to be directly due to MDS (including AML, infection and hemorrhage) was significantly higher in patients with early vs late failure, confirming the relative aggressiveness of lower-risk MDS with no response to or early relapse after ESA treatment.
In this study, only a small proportion of patients received, after failure, second-line treatments with a potential impact on progression to AML or OS, including hypomethylating agents, ATG or intensive chemotherapy, while very few were allografted (the last group was censored at the time of transplant). Analysis of prognostic factors after exclusion of those patients did not substantially modify results, although treatment received after failure was indeed associated with a clear OS advantage in the entire population (HR ¼ 0.46; 95% CI: 0.29-0.73; P ¼ 0.0011). However, longer survival in patients surviving long enough to receive second-line treatments (only available in more recent years) was considered an important bias and therefore treatment after failure was not primarily included in outcome analyses.
Overall, our results show that lower-risk MDS with anemia not responding to ESA, or relapsing within 6 months of response to ESA (in the absence of concomitant progression to more severe MDS or AML), have a relatively poor outcome, which appears independent of other risk factors generally found in lower-risk MDS and that include an excess of marrow blasts (RAEB-1) and abnormal karyotype (especially the presence of trisomy 8). 2, 8, 16 Other factors that have been associated with poorer outcome in low-and int-1-risk MDS include severe thrombocytopenia, myelofibrosis, comorbidities, transfusion burden and multilineage dysplasia. [17] [18] [19] [20] The last two parameters were not identified as independent prognostic factors in our series, while the presence of myelofibrosis and comorbidities were not systematically analyzed.
Low and int-1 IPSS patients with no response or rapid relapse after ESA may therefore be candidates for therapeutic approaches with a potential impact on survival, including hypomethylating agents, in some cases ATG with or without cyclosporine, and even allogeneic stem cell transplantation if other poor prognostic factors such as somatic gene mutations, trisomy 8 or an excess of blasts are present. By contrast, drugs tested for their effect on anemia, but without proven effect on OS, may be better indicated in patients relapsing more than 6 months after response to ESA. Our study also suggests that sensitivity or resistance to ESA should be systematically tested in lower-risk MDS with anemia before Outcome of ESA refractory/relapsing MDS patients C Kelaidi et al considering other treatment approaches aimed at improving anemia and/or with a potential impact on OS.
